Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Sunita Gulati and Sanjay Ram.

 
Connection Strength
 
 
 
7.875
 
  1. Gulati S, Schoenhofen IC, Lindhout-Djukic T, Lewis LA, Moustafa IY, Saha S, Zheng B, Nowak N, Rice PA, Varki A, Ram S. Efficacy of anti-gonococcal CMP-nonulosonate therapeutics require cathelicidins. J Infect Dis. 2020 Jul 21.
    View in: PubMed
    Score: 0.908
  2. Gulati S, Schoenhofen IC, Lindhout-Djukic T, Schur MJ, Landig CS, Saha S, Deng L, Lewis LA, Zheng B, Varki A, Ram S. Therapeutic CMP-Nonulosonates against Multidrug-Resistant Neisseria gonorrhoeae. J Immunol. 2020 May 20.
    View in: PubMed
    Score: 0.898
  3. Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 Jun 19; 17(6):e3000323.
    View in: PubMed
    Score: 0.842
  4. Gulati S, Rice PA, Ram S. Complement-Dependent Serum Bactericidal Assays for Neisseria gonorrhoeae. Methods Mol Biol. 2019; 1997:267-280.
    View in: PubMed
    Score: 0.816
  5. Gulati S, Schoenhofen IC, Whitfield DM, Cox AD, Li J, St Michael F, Vinogradov EV, Stupak J, Zheng B, Ohnishi M, Unemo M, Lewis LA, Taylor RE, Landig CS, Diaz S, Reed GW, Varki A, Rice PA, Ram S. Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics. PLoS Pathog. 2015 Dec; 11(12):e1005290.
    View in: PubMed
    Score: 0.659
  6. Gulati S, Agarwal S, Vasudhev S, Rice PA, Ram S. Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J Immunol. 2012 Apr 1; 188(7):3416-25.
    View in: PubMed
    Score: 0.507
  7. Gulati S, Sastry K, Jensenius JC, Rice PA, Ram S. Regulation of the mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1-inhibitor and alpha 2-macroglobulin. J Immunol. 2002 Apr 15; 168(8):4078-86.
    View in: PubMed
    Score: 0.256
  8. Parzych EM, Gulati S, Zheng B, Bah MA, Elliott STC, Chu JD, Nowak N, Reed GW, Beurskens FJ, Schuurman J, Rice PA, Weiner DB, Ram S. Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection. mBio. 2021 03 16; 12(2).
    View in: PubMed
    Score: 0.238
  9. Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol. 2020; 11:583305.
    View in: PubMed
    Score: 0.231
  10. Chakraborti S, Gulati S, Zheng B, Beurskens FJ, Schuurman J, Rice PA, Ram S. Bypassing phase variation of lipooligosaccharide (LOS): using heptose 1 glycan mutants to establish widespread efficacy of gonococcal 2C7 anti-LOS antibody. Infect Immun. 2019 Dec 09.
    View in: PubMed
    Score: 0.218
  11. Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. MBio. 2019 Nov 05; 10(6).
    View in: PubMed
    Score: 0.216
  12. Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 2019; 10:321.
    View in: PubMed
    Score: 0.206
  13. Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S. Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018 Sep 28.
    View in: PubMed
    Score: 0.200
  14. Ram S, Gulati S, Lewis LA, Chakraborti S, Zheng B, DeOliveira RB, Reed GW, Cox AD, Li J, St Michael F, Stupak J, Su XH, Saha S, Landig CS, Varki A, Rice PA. A novel sialylation site on Neisseria gonorrhoeae lipooligosaccharide links heptose II lactose expression with pathogenicity. Infect Immun. 2018 May 29.
    View in: PubMed
    Score: 0.196
  15. Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 Jun 01; 75(4).
    View in: PubMed
    Score: 0.183
  16. Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology. 2016 Oct; 221(10):1110-23.
    View in: PubMed
    Score: 0.170
  17. Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
    View in: PubMed
    Score: 0.166
  18. Gulati S, Mu X, Zheng B, Reed GW, Ram S, Rice PA. Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model. J Infect Dis. 2015 Jul 15; 212(2):311-5.
    View in: PubMed
    Score: 0.155
  19. Gulati S, Zheng B, Reed GW, Su X, Cox AD, St Michael F, Stupak J, Lewis LA, Ram S, Rice PA. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog. 2013; 9(8):e1003559.
    View in: PubMed
    Score: 0.141
  20. Ray TD, Lewis LA, Gulati S, Rice PA, Ram S. Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol. 2011 Apr 15; 186(8):4881-94.
    View in: PubMed
    Score: 0.119
  21. Ram S, Ngampasutadol J, Cox AD, Blom AM, Lewis LA, St Michael F, Stupak J, Gulati S, Rice PA. Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect Immun. 2007 Aug; 75(8):4071-81.
    View in: PubMed
    Score: 0.091
  22. Madico G, Ngampasutadol J, Gulati S, Vogel U, Rice PA, Ram S. Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J Immunol. 2007 Apr 1; 178(7):4489-97.
    View in: PubMed
    Score: 0.090
  23. Gulati S, Cox A, Lewis LA, Michael FS, Li J, Boden R, Ram S, Rice PA. Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. Infect Immun. 2005 Nov; 73(11):7390-7.
    View in: PubMed
    Score: 0.082
  24. Ram S, Cox AD, Wright JC, Vogel U, Getzlaff S, Boden R, Li J, Plested JS, Meri S, Gulati S, Stein DC, Richards JC, Moxon ER, Rice PA. Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem. 2003 Dec 19; 278(51):50853-62.
    View in: PubMed
    Score: 0.071
  25. Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, Mörgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a novel therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 Oct 29.
    View in: PubMed
    Score: 0.054
  26. Lewis LA, Gulati S, Burrowes E, Zheng B, Ram S, Rice PA. a-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract. MBio. 2015 Feb 03; 6(1).
    View in: PubMed
    Score: 0.039
  27. Agarwal S, Ram S, Ngampasutadol J, Gulati S, Zipfel PF, Rice PA. Factor H facilitates adherence of Neisseria gonorrhoeae to complement receptor 3 on eukaryotic cells. J Immunol. 2010 Oct 1; 185(7):4344-53.
    View in: PubMed
    Score: 0.029
  28. Ngampasutadol J, Tran C, Gulati S, Blom AM, Jerse EA, Ram S, Rice PA. Species-specificity of Neisseria gonorrhoeae infection: do human complement regulators contribute? Vaccine. 2008 Dec 30; 26 Suppl 8:I62-6.
    View in: PubMed
    Score: 0.025
  29. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008 Mar 1; 180(5):3426-35.
    View in: PubMed
    Score: 0.024
  30. Lewis LA, Ram S, Prasad A, Gulati S, Getzlaff S, Blom AM, Vogel U, Rice PA. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun. 2008 Jan; 76(1):339-50.
    View in: PubMed
    Score: 0.024
  31. Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, Lien E, Goguen J, Gulati S, Rice PA. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A. 2005 Nov 22; 102(47):17142-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.